Certain Senesco Insiders to Purchase Senesco Securities Held by Stanford Venture Capital Holdings and by Stanford International Bank

Certain Senesco Insiders to Purchase Senesco Securities Held by Stanford
Venture Capital Holdings and by Stanford International Bank

NEW BRUNSWICK, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Senesco Technologies,
Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) reported today that certain
insiders of Senesco Technologies, Inc., a Delaware corporation ("Buyers"),
have entered into definitive stock purchase agreements to purchase all of the
convertible debentures, warrants and common stock (the "Securities") of the
Company which are held by Stanford Venture Capital Holdings, Inc. and/or
Stanford International Bank, Ltd. (collectively "Seller").

The transaction is subject to the approval of the United States District Court
for the Northern District of Texas, Dallas Division, as well as other closing
conditions as further set forth in a Form 8-K, which will be filed by the
Company simultaneously herewith. Depending on the timing of Court approval,
the transaction may close in two separate closings independent of each other.

"The purchase of the Stanford position by several of the board members of
Senesco demonstrates the continued confidence and enthusiasm for the Company's
ongoing efforts. It also ensures that this position is in the hands of
individuals who hold the Company's interest in high regard. We are grateful
for their participation," noted Harlan Waksal, M.D., Senesco's Chairman of the
Board.

About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell death in
mammals (apoptosis) to determine if its technology is applicable in human
medicine. Accelerating apoptosis may have applications to the development of
cancer treatments. Delaying apoptosis may have applications to certain
diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes
its name from the scientific term for the aging of plant cells: senescence.
The Company has developed technology that regulates the onset of cell death.
Delaying cell breakdown in plants extends freshness after harvesting, while
increasing crop yields, plant size and resistance to environmental stress for
flowers, fruits and vegetables. In addition to its human health research
programs, the Company believes that its technology can be used to develop
superior strains of crops without any modification other than delaying natural
plant senescence. Senesco has partnered with leading-edge companies engaged in
agricultural biotechnology and earns research and development fees for
applying its gene-regulating platform technology to enhance its partners'
products. Senesco is headquartered in New Brunswick, N.J.

Certain statements included in this press release are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Actual results could differ materially from such statements expressed
or implied herein as a result of a variety of factors, including, but not
limited to: the ability of the Company to consummate additional financings;
the development of the Company's gene technology; the approval of the
Company's patent applications; the successful implementation of the Company's
research and development programs and joint ventures; the success of the
Company's license agreements; the successful conversion of the Company's
letter of intent into a license agreement; the acceptance by the market of the
Company's products; success of the Company's preliminary studies and
preclinical research; competition and the timing of projects and trends in
future operating performance, as well as other factors expressed from time to
time in the Company's periodic filings with the Securities and Exchange
Commission (the "SEC"). As a result, this press release should be read in
conjunction with the Company's periodic filings with the SEC. The
forward-looking statements contained herein are made only as of the date of
this press release, and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events or
circumstances.

Company Contact: Investor Relations Contact:
Senesco Technologies, Inc. FD
Bruce Galton Brian Ritchie
Chief Executive Officer (brian.ritchie@fd.com)
(bgalton@senesco.com) (212) 850-5600
(732) 296-8400

SOURCE Senesco Technologies, Inc.

Bruce Galton, Chief Executive Officer of Senesco Technologies, Inc.,
+1-732-296-8400, bgalton@senesco.com; or Investor Relations, Brian Ritchie of
FD, +1-212-850-5600, brian.ritchie@fd.com